Abstract
Background
The COVID-19 pandemic disrupted health care delivery, including cancer screening practices. This study sought to determine the impact of the COVID-19 pandemic lockdown on colorectal cancer (CRC) screening relative to social vulnerability.
Methods
Using the Medicare Standard Analytic File, individuals 65 years old or older who were eligible for guideline-concordant CRC screening between 2019 and 2021 were identified. These data were merged with the Center for Disease Control Social Vulnerability Index (SVI) dataset. Changes in county-level monthly screening volumes relative to the start of the COVID-19 pandemic (March 2020) and easing of restrictions (March 2021) were assessed relative to SVI.
Results
Among 10,503,180 individuals continuously enrolled in Medicare with no prior diagnosis of CRC, 1,362,457 (12.97%) underwent CRC screening between 2019 and 2021. With the COVID-19 pandemic, CRC screening decreased markedly across the United States (median monthly screening: pre-pandemic [n = 76,444] vs pandemic era [n = 60,826]; median Δn = 15,618; p < 0.001). The 1-year post-pandemic overall CRC screening utilization generally rebounded to pre-COVID-19 levels (monthly median screening volumes: pandemic era [n = 60,826] vs post-pandemic [n = 74,170]; median Δn = 13,344; p < 0.001). Individuals residing in counties with the highest SVI experienced a larger decline in CRC screening odds than individuals residing in low-SVI counties (reference, low SVI: pre-pandemic high SVI [OR, 0.85] vs pandemic high SVI [OR, 0.81] vs post-pandemic high SVI [OR, 0.85]; all p < 0.001).
Conclusions
The COVID-19 pandemic was associated with a decrease in CRC screening volumes. Patients who resided in high social vulnerability areas experienced the greatest pandemic-related decline.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Colorectal cancer (CRC) is the third most common cancer among both men and women in the United States.1,2 Since 1970, screening for CRC has been used as an effective method to detect precancerous polyps and early-stage cancer.3,4 According to the most up-to-date cancer screening guidelines, the United States Preventive Services Task Force (USPSTF) recommends screening for all adults ages 45 to 74 years.5 As a result, CRC incidence has notably declined by approximately 1% per year during the past decade due to the earlier diagnosis and treatment of pre-cancerous polyps during screening colonoscopies performed for this age cohort.1
In the United States, COVID-19 has been diagnosed for nearly 1 billion individuals since the declaration of a global pandemic by the World Health Organization (WHO) in March 2020.6 To mitigate transmission of the virus, various policies with an impact on outpatient care were implemented such as conversion of routine office visits into telehealth appointments and cancellation of non-urgent interventions such as screening and vaccination.7 These policies affected primary health care by redirecting resources to help with the management of the pandemic.8,9 Notably, cancer screening recommendations also were altered. The American Society for Gastrointestinal Endoscopy (ASGE) recommended the delay of routine screening colonoscopies and follow-up procedures after positive stool tests.10
Despite removal of COVID-19 restrictions, the decline in rates of screening for cancers such as breast and lung tumors have not fully recovered to date.10,11 The rate of recovery in screening deficits was notably delayed among the Medicaid or Medicare-Medicaid dual-eligible populations compared with privately insured patients.12
Potential changes in the diagnosis and management of CRC after the COVID-19 pandemic have not been well-defined. Possible changes include delays in treatment initiation and an increased incidence of advanced disease at the time of presentation.13,14,15 Previous studies have demonstrated inequalities in cancer screening among certain racial/ethnic groups and socioeconomically vulnerable populations.16,17 Moreover, the risk of CRC increases by age.18 Siegel et al.2 estimated that more than 56% of CRCs in 2023 would be diagnosed for individuals age 65 years or older.2 As such, delays in cancer screening due to the COVID-19 pandemic among older patients and a return to pre-pandemic levels after lockdown restrictions are eased may have important implications.11,19 Therefore, the current study aimed to characterize how the COVID-19 pandemic influenced CRC screening. In addition, the study sought to determine the impact of the COVID-19 pandemic lockdown on CRC screening relative to social vulnerability among a nationally representative cohort of older individuals.
Methods
Data Source and Study Population
Data were extracted from 100% Medicare Standard Analytic Files claims data obtained by the Centers for Medicare and Medicaid Services (CMS) between 2019 through 2021 to identify individuals who did and did not undergo screening for CRC.20 The CMS maintains the Medicare Standard Analytic Files (SAF), an administrative billing database that provides patient-level data on demographics, diagnoses, procedures, and expenditures.21 To be included in the analytic cohort, individuals had to have Medicare coverage and consecutive enrollment in Medicare Parts A and B for the study duration.
Only individuals age 65 years or older were included in the study cohort. The International Classification of Diseases, tenth revision (ICD-10) diagnostic and procedure codes, Current Procedural Terminology (CPT) codes, and Healthcare Common Procedure Coding System (HCPCS) codes were used to identify beneficiaries who had undergone screening for CRC.22,23 These codes included various methods for CRC screening including colonoscopies, barium enema, and fecal-occult blood test (Appendix Table S1).24
Individuals with a prior diagnosis of CRC, as identified by ICD codes, were excluded from the study cohort. This study was approved by The Ohio State University Institutional Review Board, and the need for informed patient consent was waived because the data were de-identified.
Study and Outcome Measures
Information on age, sex, race/ethnicity, geographic region, Social Vulnerability Index (SVI), and Charlson Comorbidity Index (CCI) were collected.20,25 According to the U.S. census, regions were defined as Northeast (New England, Middle Atlantic), South (South Atlantic, East South Central, and West South Central), Midwest (East North Central, West North Central), and West (Mountain, Pacific).26
The SVI, developed and maintained by the Center for Disease Control and Agency for Toxic Substances and Disease Registry, is a validated measure used to assess community vulnerability to external pressures.27 The SVI was linked with the Medicare Standard Analytical Files using county-level Federal Information Processing System (FIPS) codes and categorized into tertiles.27
The participants were categorized into three equal groups based on tertile values for SVI. The CCI was assessed using ICD-9-CM and ICD-10-CM codes and dichotomized as ≤2 versus >2.20,25 Race/ethnicity was recorded based on self-reported social constructs, which are not a reflection of genetic ancestry, and categorized as non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic other race/ethnicity.28 The non-Hispanic other race/ethnicity group was categorized as American Indians, Alaskan Natives, Native Hawaiians, Asians, Pacific Islanders, and self-reported “other” race/ethnicity groups due to small sample sizes.28
The primary outcome of interest was monthly median screening volumes for each time period. Monthly volumes of CRC screening were recorded for the entire study duration. The study duration was divided into three periods. The pre-COVID-19 pandemic period was defined as January 2019 to February 2020, whereas the COVID-19 pandemic period was defined as March 2020 to March 2021, and the post-pandemic period was defined as April 2021 to December 2021.29
Lockdown restrictions were eased throughout the country at different times and in a stepwise fashion. However, the majority of states had eased COVID-related restrictions by March 2021, so this was defined as the cutoff for the post-COVID-19 era30,31
Statistical Analyses
Continuous variables were analyzed via the Wilcoxon rank-sum test and reported as median and interquartile range (IQR). Categorical variables were compared via the chi-square test and represented as frequencies. Multivariable logistic regression models were used to assess the odds of a patient undergoing screening for CRC. Models for screening were adjusted for sex, race, age, CCI, SVI, genetic susceptibility, region, index year, and rurality (non-metropolitan vs metropolitan). The ICD codes were used to identify individuals with genetic susceptibility for malignancy (Appendix Table S2).22 Statistical analyses were performed using STATA version 18, and a two-sided significance level of α equal to 0.05 was used.
Results
Demographic Characteristics
Among 10,503,180 beneficiaries age 65 years or older who were continuously enrolled in Medicare between 2019 and 2021, 1,362,457 (12.97%) were screened for CRC. Overall, the median age was 69 years (interquartile range [IQR], 67–72 years) and approximately one half of the cohort was female (n = 5,679,955, 54.1%). The majority of the individuals (n = 8,781,793, 83.6%) had a CCI score of 2 or lower. In terms of race/ethnicity, most of the individuals were non-Hispanic White (n = 9,179,865, 87.4%), whereas a smaller proportion of individuals were non-Hispanic Black (n = 574,883, 5.5%), Hispanic (68,461, 0.7%), or non-Hispanic other (n = 679,971, 6.5%).
Most of the individuals resided in metropolitan areas (n = 8,349,172, 79.5%) in the southern (n = 4,245,230, 40.4%) or the midwestern (n = 2,281,677, 21.7%) region of the United States. Notably, the individuals from high versus low SVI counties were more likely to be non-Hispanic Black (9.4% vs 2.6%) or Hispanic (1.2% vs 0.3%) and to reside in metropolitan areas (80.6% vs 77.8%) in the southern (55.4% vs 25.0%) or western (25.8% vs 13.5%) regions of the United States (all p < 0.001; Table 1).
Association of the COVID-19 Pandemic CRC Screening Volumes with SVI
The monthly median volumes of CRC screening decreased markedly after the start of the pandemic (n = 60,826) versus before the pandemic (n = 76,444) (p < 0.001; Fig. 1). Compared with the pre-pandemic period, the monthly median CRC screening volumes during the pandemic were lower across all SVI categories as follows: low (n = 18,402 vs 23,136; median Δn = 4734 [%Δ 20.46%]), moderate (n = 22,224 vs 27,375; median Δn = 5151 [%Δ 18.78%]), high (n = 20,064 vs 25,859; median Δn = 5795 [%Δ 22.41%]) (Fig. 2). Moreover, the screening volumes were markedly lower during the COVID-19 pandemic among the male (n = 27,655 vs 33,960; median Δn = 6305 [%Δ 18.57%]) and female (n = 33,171 vs 42,400; median Δn = 9229 [%Δ 21.77%]) patients, as well as among the non-Hispanic White (n = 54,255 vs 67,242; median Δn = 12,987 [%Δ 19.31%]), non-Hispanic Black (n = 3390 vs 4121; median Δn = 731 [%Δ 17.74%]), Hispanic (n = 335 vs 456; median Δn = 121 [%Δ 26.54%]), and non-Hispanic other (n = 1600 vs 2157; median Δn = 557 [%Δ 25.82%]) individuals, (all p < 0.001).
In the post-pandemic period, after March 2021, the monthly median CRC screening volumes generally rebounded to pre-pandemic levels (n = 74,170) and were much higher than during the COVID pandemic in 2020 (n = 60,826) (p < 0.001). Notably, during the post-pandemic period versus during the pandemic in 2020, the monthly median CRC screening volumes rose among all SVI categories as follows: low SVI (n = 22,200 vs 18,402; median Δn = 3798 [%Δ 20.64%]), moderate SVI (n = 26,262 vs 22,224; median Δn = 4,038 [%Δ 18.17%]), high SVI (n = 25,258 vs 20,064; median Δn = 5,194 [%Δ 25.89%]) (p < 0.001).The median CRC screening volumes also rose among non-Hispanic White (n = 64,708 vs 54,255; median Δn = 10,453 [%Δ 19.27%]) non-Hispanic Black (n = 4156 vs 3390; median Δn = 766 [%Δ 22.60]), Hispanic (n = 444 vs 335; median Δn = 109 [%Δ 32.54%]), and non-Hispanic other (n = 2192 vs 1600; median Δn = 592 [%Δ 37.00%]) individuals (all p < 0.001) (Table 2).
Interestingly, there was marked geographic variation in the decline, as well as an increase in CRC screening volumes across the United States (Figs. 3 and 4). Notably, the Northeastern region had the greatest decline in CRC screening (n = 10,123 vs 13,586; median Δn = 3,436 [%Δ 25.29%]) and experienced a marked increase (n = 13,431 vs 10,123; median Δn = 3308 [%Δ 32.68%]) after the easing of lockdown restrictions. In contrast, the Southern region of the United States experienced the least fluctuation in CRC screening volumes during the COVID-19 pandemic: decrease (n = 20,172 vs 24,386; median Δn = 4214 [%Δ 17.28%]); increase (n = 22,656 vs 20,172; median Δn = 2484 [%Δ 12.31%]).
In the multivariable logistic regression analysis, residence in high SVI counties was associated with lower odds of screening for CRC, especially during the pandemic era (pre-pandemic [high SVI: OR, 0.85; 95% CI, 0.84–0.85], pandemic era [high SVI: OR, 0.81; 95% CI, 0.81–0.82], post-pandemic [high SVI: OR 0.85; 95% CI, 0.85–0.86]; p < 0.001). Similarly, Hispanic and patients who self-identified as “other race” also were associated with lower odds of screening across all periods, with the lowest odds noted during the pandemic era (reference [non-Hispanic White]; pre-pandemic [Hispanic: OR, 0.88; 95% CI, 0.85–0.91; other race: OR, 0.86; 95% CI, 0.85–0.88]; pandemic era [Hispanic: OR, 0.75; 95% CI, 0.54–0.82; other race: OR, 0.79; 95% CI, 0.78-0.81]; post-pandemic [Hispanic: OR, 0.78; 95% CI, 0.74–0.82; other race: OR, 0.89; 95% CI, 0.87–0.91]; p < 0.001). In contrast, patients who self-identified as Black were associated with increased odds of screening for CRC throughout the study period. (reference [non-Hispanic White]; pre-pandemic [non-Hispanic Black: OR, 1.04; 95% CI, 1.02–1.05]; pandemic era [non-Hispanic Black: OR, 1.06; 95% CI, 1.04–1.07]; post-pandemic [non-Hispanic Black: OR, 1.07; 95% CI, 1.06–1.09]; p < 0.001) (Table 3).
Discussion
According to the American Cancer Society, there would be 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer in the United States in 2023.32 Prior studies have demonstrated that earlier diagnosis of CRC is associated with a significantly higher 5-year survival (> 90%).32 Screening for CRC may serve as a highly effective and efficient tool to identify pre-cancerous or early CRC.33 Various methods for screening CRC have been introduced in the past few decades, including colonoscopy, sigmoidoscopy, double-contrast barium enema, computed tomographic colonography, fecal occult blood test, and fecal DNA tests.33,34,35 The declaration of a global pandemic by the World Health Organization (WHO) in March 2020 led to a drastic decrease in health care delivery and screening worldwide.36,37,38,39,40 Although previous research has assessed the impact of the COVID-19 pandemic on screening for other cancers, the effect of lockdown restrictions on CRC screening volumes, especially among vulnerable populations, remains ill-defined.13,36 The current study was important because we specifically characterized the decline in CRC screening during the pandemic, as well as the subsequent recovery in screening volumes relative to county-level SVI and race/ethnicity in a nationally representative cohort. Notably, median monthly CRC screening volumes declined drastically in 2020 after the implementation of lockdown restrictions, with socially vulnerable populations affected the most. Patients living in counties with high social vulnerability experienced the greatest pandemic-related decline.
The COVID-19 pandemic began in early 2020 and caused a substantial lockdown in the United States during March of that year.29 The pandemic placed an enormous burden on the health care system, leading to challenges that had a great impact on the ability to deliver health care services effectively.41 In particular, the pandemic had a significant impact on screening, causing a sharp decline in global screening rates for all cancers.13,37,42 The dramatic decrease in screening was undoubtedly due to cancellations of elective and planned procedures, as well as a decrease in public transport, loss of income to pay for services, and a shift in the health workforce toward COVID-19 services.43,44 To this point, Chen et al.36 reported that CRC screening rates were 13.1% lower in July 2020 than in July 2019. Similarly, Tinmouth et al.45 reported a 60% reduction in colonoscopies performed during 2020 versus 2019 in Canada. Other studies conducted in the Netherlands, Poland, United Kingdom, Israel, and Croatia also reported a decline in cancer screening in 2020 compared with pre-pandemic years.46,47,48,49 Furthermore, patients with a high SVI were more likely to be affected by COVID-19-related illnesses, which disproportionately affected their odds of being screened during the pandemic.50 In line with these studies, the current study noted a substantial decrease in median CRC screening volumes during 2020 after implementation of lockdown restrictions due to the COVID-19 pandemic. Interestingly, the post-pandemic screening rate did not rebound to pre-pandemic levels or surpass them. This may have been due to patient reluctance to seek medical care in the post-pandemic setting, as well as difficulty accessing cancer screening due to additional financial burdens related to the pandemic. Elderly patients and patients with comorbidities, who were at higher risk for serious complications from COVID-19, may have been specifically affected by these factors. Another reason for the smaller rebound in post-pandemic screening may have been the expansion of screening guidelines to include individuals 45 years old at a time when the physician workforce was constrained by pandemic-related challenges. Of particular note, individuals with moderate or high SVI had lower odds of screening before, during, and after the pandemic, with the worst odds reported for individuals residing in high-SVI areas during the pandemic. These findings highlight that socially vulnerable populations were most affected by pandemic-related policy changes.
Variations in cancer screening due to race/ethnicity, language, disability, and social demographics have been described.16,43,44,45,46 The COVID-19 pandemic exacerbated the obstacles faced by marginalized communities, resulting in restricted access to health care services such as cancer prevention and care.41,51,52,53 To this point, SVI may serve as a composite tool to assess key social determinants of health and provide insight into barriers for health care access and utilization. Bauer et al.16 reported that areas characterized by high SVI were associated with reduced screening rates. Moreover, individuals from high-SVI counties may not have access to effective transportation for travel to cancer screening facilities.54,55 Despite efforts to improve access to health care, patients who reside in moderate- and high-SVI areas still experience disparities in access to cancer prevention services.16,56 Building on previous work, the current study demonstrated that individuals in the high socially vulnerable areas experienced the lowest odds of CRC screening during the pandemic. In turn, these data serve to illustrate the ongoing need to address and bridge gaps in access to cancer prevention care.57,56,58,59,60 During 2021, numerous countries resumed their cancer screening programs and implemented strategies to boost screening rates.61,62,63 Additionally, efforts were made to ensure that individuals who missed their cancer screenings during to the pandemic were given priority and screened first.62,63 Resumption of these programs, complemented by the relaxation in pandemic lockdowns and increase in tele-medicine services, improved access to health care services globally.64,65 Interestingly, data from the current study demonstrated disparate access to CRC screening among various racial/ethnic groups. For example, Hispanic and other non-White racial/ethnic groups experienced a decline in the odds of CRC screening during the pandemic that did not recover to pre-pandemic levels. Barriers such as language difficulties, insurance status, limited health literacy, reduced awareness of preventive health care, and cultural differences may preclude certain racial/ethnic groups from accessing health services, which may worsen disparities in cancer prevention.66 Recently, health care organizations and policymakers have sought to improve access to care through initiation of the Affordable Care Act, as well as through outreach programs, mobile screening vans, and community-based awareness initiatives.67,68 In turn, these efforts may mitigate race/ethnicity-based disparities in cancer screening among non-Hispanic White and non-Hispanic Black individuals.69,70 In fact, non-Hispanic Black individuals may be more likely than non-Hispanic White individuals to be up to date relative to cancer screening.71
The current study may have important implications for health care institutions, payers, policymakers, and professional organizations. For example, the data offer evidence to support implementation of community policies and related initiatives focused on investment and promotion of structural equity within cancer prevention systems. Socially vulnerable patients from disadvantaged communities face additional barriers that preclude access to cancer care prevention. Therefore, focused efforts to coordinate health care delivery systems, screening for social determinants during clinical encounters, utilization of telehealth services, and home-based screening methods are needed to improve cancer care equity. The Colorectal Cancer Control Program (CRCCP), operated by the Centers for Disease Control and Prevention (CDC), offers financial support to states and Native American tribes with the aim of improving CRC screening rates among underserved groups.72 This initiative is focused on providing screening and follow-up services to individuals with low income and limited or no insurance coverage. The National Colorectal Cancer Roundtable (NCCRT) is a coalition of various organizations from the public, private, and voluntary sectors, that is also working to increase CRC screening rates across the country.73 Similar to CRCCP, their efforts primarily target low-income and underrepresented communities through initiatives such as public education campaigns, provider training, and policy advocacy. Health care providers and organizations must work together to improve screening of CRC patients, especially among vulnerable populations, to improve the quality of cancer prevention services.
The current study should be interpreted with consideration of several limitations. Because only Medicare beneficiaries were examined, the findings may not be generalizable to younger individuals.74 Although most screening methods are covered under Medicare, home testing kits using fecal occult blood tests may not fall under the coverage. Moreover, use of administrative data may be associated with data miscoding and misclassification errors. To address this, we used ICD-10-CM diagnosis codes previously demonstrated to have high fidelity for administrative data use.75 The Medicare data were available only until December 2021. As a result, the period after COVID-19 was not fully captured, leading to the utilization of monthly median screening volumes instead of overall screening rates. Moreover, the impact of the COVID-19 pandemic on different screening methods, including colonoscopy, fecal occult blood testing, and CT colonography, could not be assessed due to database limitations. The current study examined only CRC screening. Future studies need to assess the impact of the decrease in screening on the incidence of late-stage CRC and CRC mortality. The current study could not assess the percentage of individuals recommended for screening who were up to date with their screening according to USPSTF screening guidelines due to the limited study duration.
In conclusion, the COVID-19 pandemic caused a sharp decline in CRC screening after March 2020 that was followed by a recovery to near pre-pandemic levels after easing of restrictions in 2021. Individuals with high SVI and certain racial/ethnic groups experienced the greatest decline in screening volumes during the COVID pandemic. These data highlight the need to address social determinants of health to alleviate disparities in cancer care prevention.
Data Availability
The data for this study were obtained from the Medicare Standard Analytic Files. There are restrictions to the availability of these data, which were used under license for this study. Data can be accessed with permission from the Centers for Medicare and Medicaid Services.
References
Colorectal Cancer Statistics | How common is colorectal cancer? Retrieved 15 July 2023 at https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html.
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54. https://doi.org/10.3322/caac.21772.
Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547–56. https://doi.org/10.1056/NEJMoa2208375.
Jain S, Maque J, Galoosian A, Osuna-Garcia A, May FP. Optimal strategies for colorectal cancer screening. Curr Treat Options Oncol. 2022;23:474–93. https://doi.org/10.1007/s11864-022-00962-4.
US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2021;325:1965–77. https://doi.org/10.1001/jama.2021.6238.
WHO Coronavirus (COVID-19) Dashboard. Retrieved 19 July 2023 at https://covid19.who.int.
Mafi JN, Craff M, Vangala S, et al. Trends in US ambulatory care patterns during the COVID-19 pandemic, 2019–2021. JAMA. 2022;327:237–47. https://doi.org/10.1001/jama.2021.24294.
Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Intern Med. 2021;181:388–91. https://doi.org/10.1001/jamainternmed.2020.5928.
Morris EJA, Goldacre R, Spata E, et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol. 2021;6:199–208. https://doi.org/10.1016/S2468-1253(21)00005-4.
Doan C, Li S, Goodwin JS. Breast and lung cancer screening among medicare enrollees during the COVID-19 pandemic. JAMA Netw Open. 2023;6:e2255589. https://doi.org/10.1001/jamanetworkopen.2022.55589.
Peacock HM, Tambuyzer T, Verdoodt F, et al. Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis. ESMO Open. 2021;6:100197. https://doi.org/10.1016/j.esmoop.2021.100197.
ASGE Gastroenterology Professional Society guidance on endoscopic procedures during the COVID-19 pandemic. Retrieved 19 July 2023 at https://www.asge.org/home/resources/key-resources/covid-19-asge-updates-for-members/gastroenterology-professional-society-guidance-on-endoscopic-procedures-during-the-covid-19-pandemic.
Mazidimoradi A, Tiznobaik A, Salehiniya H. Impact of the COVID-19 pandemic on colorectal cancer screening: a systematic review. J Gastrointest Cancer. 2022;53:730–44. https://doi.org/10.1007/s12029-021-00679-x.
Rottoli M, Gori A, Pellino G, et al. Colorectal cancer stage at diagnosis before vs during the COVID-19 pandemic in Italy. JAMA Network Open. 2022;5:e2243119. https://doi.org/10.1001/jamanetworkopen.2022.43119.
Meijer J, Elferink MAG, van Hoeve JC, et al. Impact of the COVID-19 pandemic on colorectal cancer care in the Netherlands: a population-based study. Clin Colorectal Cancer. 2022;21:e171–8. https://doi.org/10.1016/j.clcc.2022.02.005.
Bauer C, Zhang K, Xiao Q, Lu J, Hong YR, Suk R. County-level social vulnerability and breast, cervical, and colorectal cancer screening rates in the US, 2018. JAMA Netw Open. 2022;5:e2233429. https://doi.org/10.1001/jamanetworkopen.2022.33429.
Moazzam Z, Woldesenbet S, Endo Y, et al. Association of historical redlining and present-day social vulnerability with cancer screening. J Am Coll Surg. 2022. https://doi.org/10.1097/XCS.0000000000000779.
Singh KE, Taylor TH, Pan CJG, Stamos MJ, Zell JA. Colorectal cancer incidence among young adults in California. J Adolesc Young Adult Oncol. 2014;3:176–84. https://doi.org/10.1089/jayao.2014.0006.
Lee B, Young S, Williams R, Liang PS. Impact of the COVID-19 pandemic on colorectal cancer screening in New York City. J Med Screen. 2023;30:81–6. https://doi.org/10.1177/09691413221128666.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8.
What’s Medicare? | Medicare. Retrieved 4 June 2023 at https://www.medicare.gov/what-medicare-covers/your-medicare-coverage-choices/whats-medicare.
Free 2023 ICD-10-CM Codes. Retrieved 8 June 2023 at https://www.icd10data.com/ICD10CM/Codes.
ICD – ICD-9-CM – International classification of diseases, ninth revision, clinical modification. Published 3 November 2021. Retrieved 8 June 2023 at https://www.cdc.gov/nchs/icd/icd9cm.htm.
HCPCS Codes & Modifiers Lookup, HCPCS Codes List–Codify by AAPC. Retrieved 31 July 2023 at https://www.aapc.com/codes/hcpcs-codes-range/0.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9. https://doi.org/10.1016/0895-4356(92)90133-8.
Bureau UC. Geographic Levels. Census.gov. Retrieved 31 July 2023 at https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html.
CDC/ATSDR SVI Data and documentation download | Place and Health | ATSDR. Published 22 December 2022. Retrieved 4 June 2023 at https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html.
Flanagin A, Frey T, Christiansen SL. AMA Manual of Style Committee. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326:621–7. https://doi.org/10.1001/jama.2021.13304.
CDC Museum COVID-19 Timeline. Centers for disease control and prevention. Published 15 March 2023. Retrieved 18 July 2023 at https://www.cdc.gov/museum/timeline/covid19.html.
Coronavirus closures: map of where US states are tightening restrictions. Retrieved 4 August 2023 at https://www.usatoday.com/storytelling/coronavirus-reopening-america-map/.
COVID Restrictions are being lifted in these states. Retrieved 4 August 2023 at https://www.newsweek.com/us-states-covid-restrictions-eased-mask-mandates-lifted-1573443.
Colorectal Cancer Statistics | How common is colorectal cancer? Retrieved 18 July 2023 at https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html.
Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418–32. https://doi.org/10.1053/j.gastro.2019.06.043.
Bretthauer M. Colorectal cancer screening. J Int Med. 2011;270:87–98. https://doi.org/10.1111/j.1365-2796.2011.02399.x.
Winawer SJ. Colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2007;21:1031–48. https://doi.org/10.1016/j.bpg.2007.09.004.
Chen RC, Haynes K, Du S, Barron J, Katz AJ. Association of cancer screening deficit in the United States with the COVID-19 pandemic. JAMA Oncol. 2021;7:878–84. https://doi.org/10.1001/jamaoncol.2021.0884.
Fagundes TP, Albuquerque RM, Miranda DLP, et al. (1992) Dealing with cancer screening in the COVID-19 era. Rev Assoc Med Bras. 2021;67(1):86–90. https://doi.org/10.1590/1806-9282.67.Suppl1.20200889.
Gorin SNS, Jimbo M, Heizelman R, Harmes KM, Harper DM. The future of cancer screening after COVID-19 may be at home. Cancer. 2021;127:498–503. https://doi.org/10.1002/cncr.33274.
Moubarak S, Merheb D, Basbous L, Chamseddine N, Bou Zerdan M, Assi HI. COVID-19 and lung cancer: update on the latest screening, diagnosis, management, and challenges. J Int Med Res. 2022;50:3000605221125047. https://doi.org/10.1177/03000605221125047.
Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium, Figueroa JD, Gray E, et al. (2021) The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 151: 106585. Doi: https://doi.org/10.1016/j.ypmed.2021.106585
Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives. Best Pract Res Clin Anaesthesiol. 2021;35:293–306. https://doi.org/10.1016/j.bpa.2020.11.009.
Fedewa SA, Cotter MM, Wehling KA, Wysocki K, Killewald R, Makaroff L. Changes in breast cancer screening rates among 32 community health centers during the COVID-19 pandemic. Cancer. 2021;127:4512–5. https://doi.org/10.1002/cncr.33859.
Haileamlak A. The impact of COVID-19 on health and health systems. Ethiop J Health Sci. 2021;31:1073–4. https://doi.org/10.4314/ejhs.v31i6.1.
COVID-19 Significantly Impacts Health Services for Noncommunicable Diseases. Retrieved 25 July 2023 at https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases.
Tinmouth J, Dong S, Stogios C, et al. Estimating the backlog of colonoscopy due to coronavirus disease 2019 and comparing strategies to recover in Ontario. Canada Gastroenterol. 2021;160:1400-2.e1. https://doi.org/10.1053/j.gastro.2020.11.048.
Kirac I, Misir Z, Vorih V, Ćurt L, Šekerija M, Antoljak N. The impact of COVID-19 epidemiological restriction guidelines measures in a Croatian tertiary colorectal cancer center. Libri Oncologici: Croatian J Oncol. 2020;48:43–6. https://doi.org/10.20471/LO.2020.48.02-03.08.
Longcroft-Wheaton G, Tolfree N, Gangi A, Beable R, Bhandari P. Data from a large Western centre exploring the impact of COVID-19 pandemic on endoscopy services and cancer diagnosis. Frontline Gastroenterol. 2021;12:193–9. https://doi.org/10.1136/flgastro-2020-101543.
Vernooij F, Heintz APM, Coebergh JW, Massuger LFAG, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009;112:455–61. https://doi.org/10.1016/j.ygyno.2008.11.011.
Lahat A, Benjamin A. Changes in policy and endoscopic procedures during the 2019 coronavirus disease outbreak: a single-center experience. Clin Endosc. 2021;54:48–54. https://doi.org/10.5946/ce.2020.132.
Tan SY, Foo CD, Verma M, et al. Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: lessons for improving health and social equity. Soc Sci Med. 2023;328:116007. https://doi.org/10.1016/j.socscimed.2023.116007.
Morgan Z, Bazemore A, Dai M, Peterson L. Racial and ethnic disparities in access to primary care during COVID-19. Ann Fam Med. 2022;20(1):790. https://doi.org/10.1370/afm.20.s1.2790.
Raine S, Liu A, Mintz J, Wahood W, Huntley K, Haffizulla F. Racial and ethnic disparities in COVID-19 outcomes: social determination of health. Int J Environ Res Public Health. 2020;17:8115. https://doi.org/10.3390/ijerph17218115.
Patel MI, Ferguson JM, Castro E, et al. Racial and ethnic disparities in cancer care during the COVID-19 pandemic. JAMA Netw Open. 2022;5:e2222009. https://doi.org/10.1001/jamanetworkopen.2022.22009.
Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Commun Health. 2013;38:976–93. https://doi.org/10.1007/s10900-013-9681-1.
Wray AJD, Minaker LM. Is cancer prevention influenced by the built environment? A multidisciplinary scoping review. Cancer. 2019;125:3299–311. https://doi.org/10.1002/cncr.32376.
Korn AR, Walsh-Bailey C, Correa-Mendez M, et al. Social determinants of health and US cancer screening interventions: a systematic review. CA Cancer J Clin. 2023. https://doi.org/10.3322/caac.21801.
Coughlin SS, King J, Richards TB, Ekwueme DU. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002. Cancer Epidemiol Biomarkers Prev. 2006;15:2154–9. https://doi.org/10.1158/1055-9965.EPI-05-0914.
Akinlotan MA, Weston C, Bolin JN. Individual- and county-level predictors of cervical cancer screening: a multi-level analysis. Public Health. 2018;160:116–24. https://doi.org/10.1016/j.puhe.2018.03.026.
Chan DNS, Law BMH, Au DWH, So WKW, Fan N. A systematic review of the barriers and facilitators influencing the cancer screening behaviour among people with intellectual disabilities. Cancer Epidemiol. 2022;76:102084. https://doi.org/10.1016/j.canep.2021.102084.
Santiago-Rodríguez EJ, Rivadeneira NA, Torres JM, Sarkar U, Hiatt RA. Socioeconomic status and colorectal cancer screening behaviors in a vulnerable multiethnic population. Ethn Health. 2022;27:980–96. https://doi.org/10.1080/13557858.2020.1838454.
Partanen VM, Heinävaara S, Waldstrøm M, et al. Adherence to international recommendations in the governance and organization of Nordic cervical cancer screening programmes. Acta Oncol. 2020;59:1308–15. https://doi.org/10.1080/0284186X.2020.1821089.
Pairawan SS, Olmedo Temich L, de Armas S, et al. Recovery of screening mammogram cancellations during COVID-19. Am Surg. 2021;87:1651–5. https://doi.org/10.1177/00031348211051695.
de Lima PN, van den Puttelaar R, Hahn AI, et al. Unequal recovery in colorectal cancer screening following the COVID-19 pandemic. medRxiv. 2022;26:22283887. https://doi.org/10.1101/2022.12.23.22283887.
Webber EC, McMillen BD, Willis DR. Health care disparities and access to video visits before and after the COVID-19 pandemic: findings from a patient survey in primary care. Telemed J E Health. 2022;28:712–9. https://doi.org/10.1089/tmj.2021.0126.
Vanni G, Materazzo M, Pellicciaro M, Caspi J, Capacci A, Merra G. Access to health care after COVID-19 pandemic: is it time for telemedicine? Eur Rev Med Pharmacol Sci. 2020;24:9778–9. https://doi.org/10.26355/eurrev_202010_23185.
Barberan Parraga C, Singh R, Lin R, Tamariz L, Palacio A. Colorectal cancer screening disparities among race: a zip code-level analysis. Clin Colorect Cancer. 2023;22:183–9. https://doi.org/10.1016/j.clcc.2023.01.001.
Affordable Care Act (ACA)–Glossary. HealthCare.gov. Retrieved 7 August 2023 at https://www.healthcare.gov/glossary/affordable-care-act.
Reducing Health Disparities. Centers for Disease Control and Prevention. Published 25 July 2022. Retrieved 7 August 2023 at https://www.cdc.gov/nccdphp/dnpao/state-local-programs/reach/index.htm.
May FP, Glenn BA, Crespi CM, Ponce N, Spiegel BMR, Bastani R. Decreasing black-white disparities in colorectal cancer incidence and stage at presentation in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:762–8. https://doi.org/10.1158/1055-9965.EPI-16-0834.
Doubeni CA, Corley DA, Zhao W, Lau Y, Jensen CD, Levin TR. Association between improved colorectal screening and racial disparities. N Engl J Med. 2022;386:796–8. https://doi.org/10.1056/NEJMc2112409.
Sauer AG, Liu B, Siegel RL, Jemal A, Fedewa SA. Comparing cancer screening estimates: behavioral risk factor surveillance system and national health interview survey. Prev Med. 2018;106:94–100. https://doi.org/10.1016/j.ypmed.2017.10.019.
Colorectal Cancer Control Program (CRCCP) | CDC. Published 13 March 2023. Retrieved 3 August 2023 at https://www.cdc.gov/cancer/crccp/index.htm.
Front Page–National Colorectal Cancer Roundtable. Retrieved 4 August 2023 at https://nccrt.org/.
Division (DCD) DC. Who’s eligible for Medicare? HHS.gov. Published 9 February 12AD. Retrieved 20 July 2023 at https://www.hhs.gov/answers/medicare-and-medicaid/who-is-eligible-for-medicare/index.html.
Quan H, Li B, Duncan Saunders L, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res. 2008;43:1424–41. https://doi.org/10.1111/j.1475-6773.2007.00822.x.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
DISCLOSURES
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Khan, M.M.M., Munir, M.M., Woldesenbet, S. et al. Association of COVID-19 Pandemic with Colorectal Cancer Screening: Impact of Race/Ethnicity and Social Vulnerability. Ann Surg Oncol 31, 3222–3232 (2024). https://doi.org/10.1245/s10434-024-15029-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-15029-x